Amneal launches Mesalamine; receives U.S. FDA Lenalidomide approval
Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD ® - Lenalidomide capsules, referencing REVLIMID ® BRIDGEWATER, N.J., February 19, 2025--(BUSINESS WIRE)--Amnea ...
Pulse27 天
UK researchers uncover ethnic differences in inflammatory bowel disease
No differences were seen in use of 5-aminosalicylate, corticosteroid, thiopurine, anti-TNF or vedolizumab use with consistency across South Asian and white populations. There were also no differences ...